Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates deubiquitinase USP5 in tumor cells

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway has emerged as a cancer therapeutic target. However, clinical trials have proven that most human cancers are resistant to TRAIL. We show that exposure to recombinant TRAIL resulted in the accumulation of ubiquitinated proteins and free ubiquitin polymers, suggesting a link between TRAIL and the ubiquitin (Ub)-proteasome pathway. TRAIL treatment in cancer cells reduced the activity and cleavage of USP5, a deubiquitinase (DUB) previously shown to target unanchored Ub polymers and regulate p53-mediated transcription. TRAIL was effective in suppressing USP5 activity and cleavage in TRAIL-sensitive cells but not resistant cells. Knockdown of USP5 in TRAIL-resistant cells demonstrated that USP5 controls apoptotic responsiveness to TRAIL. USP5 cleavage and ubiquitination were blocked by caspase-8 specific inhibitors. A small-molecule USP5/9× inhibitor (G9) combined with TRAIL enhanced apoptosis and blocked colony growth in highly TRAIL-resistant cell lines. Finally, USP5 protein levels and activity were found to be frequently deregulated in TRAIL-resistant cells. Together, we conclude that activated TRAIL enhances USP5 activity and induces apoptosis in TRAIL-sensitive and -resistant cells. We also suggest that USP5 inhibition may be effective in inducing apoptotic thresholds to enhance responsiveness to TRAIL.

[1]  Young-Jun Jeon,et al.  DR4-Ser424 O-GlcNAcylation Promotes Sensitization of TRAIL-Tolerant Persisters and TRAIL-Resistant Cancer Cells to Death. , 2019, Cancer research.

[2]  W. El-Deiry,et al.  TRAIL pathway targeting therapeutics , 2018, Expert review of precision medicine and drug development.

[3]  H. Walczak,et al.  Paving TRAIL's Path with Ubiquitin. , 2018, Trends in biochemical sciences.

[4]  Kumar Selvarajoo,et al.  A systems biology approach to overcome TRAIL resistance in cancer treatment. , 2017, Progress in biophysics and molecular biology.

[5]  H. Walczak,et al.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy , 2017, Nature Reviews Cancer.

[6]  Peter C. Hollenhorst,et al.  Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma , 2017, Nature Communications.

[7]  Jianping Jin,et al.  Regulation of Linear Ubiquitin Chain Assembly Complex by Caspase-Mediated Cleavage of RNF31 , 2016, Molecular and Cellular Biology.

[8]  R. Yu,et al.  TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill , 2015, BMC Cancer.

[9]  A. Jakubowiak,et al.  Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. , 2015, Blood.

[10]  D. P. Mishra,et al.  Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells , 2015, Front. Oncol..

[11]  N. Donato,et al.  Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway , 2014, Oncotarget.

[12]  P. Holland.  Death receptor agonist therapies for cancer, which is the right TRAIL? , 2014, Cytokine & growth factor reviews.

[13]  F. Chan,et al.  CYLD Deubiquitinates RIP1 in the TNFα-Induced Necrosome to Facilitate Kinase Activation and Programmed Necrosis , 2013, PloS one.

[14]  J. Olson,et al.  A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. , 2012, Cancer discovery.

[15]  G. Dianov,et al.  Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. , 2011, Chemistry & biology.

[16]  A. Yang,et al.  Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. , 2010, Current opinion in cell biology.

[17]  N. Donato,et al.  Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. , 2010, Cancer research.

[18]  D. Lawrence,et al.  Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling , 2009, Cell.

[19]  S. de Jong,et al.  TRAIL receptor signalling and modulation: Are we on the right TRAIL? , 2009, Cancer treatment reviews.

[20]  D. Lane,et al.  Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53* , 2009, Journal of Biological Chemistry.

[21]  S. Fulda,et al.  Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy , 2006, Oncogene.

[22]  Mark Boothby,et al.  Faculty Opinions recommendation of The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. , 2006 .

[23]  K. Schulze-Osthoff,et al.  The Proteasome Is Required for Rapid Initiation of Death Receptor-Induced Apoptosis , 2006, Molecular and Cellular Biology.

[24]  Ivan Dikic,et al.  Ubiquitylation and cell signaling , 2005, The EMBO journal.

[25]  A. Kraft,et al.  The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim , 2005, Molecular Cancer Therapeutics.

[26]  Hui-Chen Hsu,et al.  Regulation of apoptosis proteins in cancer cells by ubiquitin , 2004, Oncogene.

[27]  I. Jeremias,et al.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.

[28]  H. Naganuma,et al.  A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents , 2003, British Journal of Cancer.

[29]  C. Pickart,et al.  Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.

[30]  J. Tschopp,et al.  TRAIL receptor-2 signals apoptosis through FADD and caspase-8 , 2000, Nature Cell Biology.

[31]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[32]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[33]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.